Viking Therapeutics starts Phase 3 trials for oral obesity drug VK2735

October 14, 2026 7:05 AM

Viking Therapeutics, Inc. (NASDAQ: VKTX) has initiated two Phase 3 clinical trials, SUNRISE-1 and SUNRISE-2, to evaluate an oral formulation ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found